Predicting BPH Surgery Outcomes Using a Preoperative Scoring System

Development and Clinical Application Value of a Predictive Scoring System for Postoperative Outcomes Following Transurethral Resection of the Prostate Based on Preoperative Multidimensional Objective Indicators

This study aims to develop and validate a preoperative predictive scoring system for surgical outcomes in patients with benign prostatic hyperplasia (BPH) undergoing prostate surgery (including but not limited to transurethral resection of the prostate, laser enucleation, photoselective vaporization, or robot-assisted simple prostatectomy).

It is a multicenter retrospective study involving patients from four hospitals in China. Preoperative multidimensional objective indicators, including clinical data, prostate MRI parameters, and urodynamic measurements, will be collected. The primary outcome is a favorable surgical response defined by a postoperative-to-preoperative International Prostate Symptom Score (IPSS) ratio ≤ 0.5 at 6 months after surgery.

Multivariable logistic regression, restricted cubic splines, and bootstrap internal validation will be used to construct and evaluate the scoring system. The goal is to provide an objective, individualized tool for optimizing surgical decision-making in BPH patients.

Study Overview

• Status: Not yet recruiting
• Conditions: BPH (Benign Prostatic Hyperplasia)

• Study Type: Observational
• Enrollment (Estimated): 2000

Contacts and Locations

• Study Contact: Name: Yong Wei; Phone Number: 13960985927; Email: drzhuzh@163.com

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult; Older Adult
• Accepts Healthy Volunteers: No

• Sampling Method: Non-Probability Sample

Study Population

This study population consists of adult male patients diagnosed with benign prostatic hyperplasia (BPH) who underwent prostate surgery (including transurethral resection of the prostate, laser enucleation, photoselective vaporization, or robot-assisted simple prostatectomy) between January 1, 2020 and August 30, 2025. Participants were recruited from four hospitals in China: The First Affiliated Hospital of Fujian Medical University, Fujian Medical University Union Hospital, Fuzhou Hospital of Traditional Chinese Medicine, and The First People's Hospital of Yunnan Province. All patients are of Chinese ethnicity and were selected based on the eligibility criteria described above. No specific community-based recruitment or sampling methods were applied; all consecutive eligible patients during the study period were included.

Description

Inclusion Criteria:

• - Postoperative pathological diagnosis of benign prostatic hyperplasia (BPH)
• Completion of pelvic or prostate magnetic resonance imaging (MRI) plain scan within 1 month before surgery
• Completion of urodynamic study within 1 month before surgery
• Completion of International Prostate Symptom Score (IPSS) both before and after surgery
• Complete and retrievable clinical and pathological data
• Generally good condition without infection, autoimmune disease, hematologic disease, or other malignancies
• Complete follow-up data with follow-up duration of at least 6 months after surgery

Exclusion Criteria:

• - Concomitant prostate cancer or other malignancies
• Prior prostate surgery or pelvic radiotherapy
• Severe cardiac, pulmonary, hepatic, or renal insufficiency precluding tolerance of surgery
• Intraoperative or postoperative severe complications affecting efficacy assessment
• Follow-up duration less than 6 months or missing key data
• Poor patient compliance precluding completion of necessary assessments and follow-up
• Incomplete clinical, imaging, urodynamic, or pathological data, or loss to follow-up

Study Plan

How is the study designed?

Number of groups / cohorts

1

Cohorts and Interventions

Group / Cohort
BPH Patients Undergoing Prostate Surgery; Patients with BPH who underwent prostate surgery (various techniques including TURP, laser enucleation, PVP, or RASP) between Jan 2020 and Aug 2025 across four centers. Preoperative MRI and urodynamic data collected. Primary outcome: IPSS ratio ≤0.5 at 6 months post-surgery.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Proportion of patients with favorable surgical response at 6 months post-surgery	Favorable surgical response is defined as a ratio of postoperative International Prostate Symptom Score (IPSS) to preoperative IPSS ≤ 0.5 at 6 months after surgery. IPSS assesses lower urinary tract symptoms, with scores ranging from 0 to 35 (higher scores indicating more severe symptoms). A ratio ≤ 0.5 represents at least 50% improvement from baseline.	6 months after surgery

Collaborators and Investigators

• Sponsor: First Affiliated Hospital of Fujian Medical University

Study record dates

Study Major Dates

• Study Start (Estimated): June 1, 2026
• Primary Completion (Estimated): May 1, 2027
• Study Completion (Estimated): September 1, 2027

Study Registration Dates

• First Submitted: May 29, 2026
• First Submitted That Met QC Criteria: May 29, 2026
• First Posted (Actual): June 3, 2026

Study Record Updates

• Last Update Posted (Actual): June 3, 2026
• Last Update Submitted That Met QC Criteria: May 29, 2026
• Last Verified: April 1, 2026

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Urogenital Diseases; Genital Diseases; Genital Diseases, Male; Prostatic Diseases; Male Urogenital Diseases; Prostatic Hyperplasia
• Other Study ID Numbers: 20260301102406738

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: UNDECIDED
• IPD Plan Description: IPD may not be shared due to concerns about patient privacy, lack of explicit informed consent for data sharing, and restrictions imposed by local ethics committees and institutional data protection policies. Any request for data sharing would need to be reviewed by the ethics committee of each participating hospital.

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No